产品描述信息
NR-699??SARS coronavirus, Nucleocapsid (N) Protein, Recombinant from E. coli(Proteins)|SARS coronavirus|Nucleocapsid (N) Protein, Recombinant from E. coli|-20°C|NIH Biodefense and Emerging Infections Research Resources RepositoryAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-CoV Nucleocapsid (N) Protein, Recombinant from E. coli, NR-699."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
This item is currently in our production queue. Please allow ample time for distribution lots to be made available.
NR-699 was expressed and purified using a novel SUMO fusion system. An N-terminal histidine-tagged SUMO-nucleocapsid fusion was expressed in E. coli and purified by nickel affinity chromatography. After the fusion was cleaved by the SUMO protease, the SUMO tag and the SUMO protease (both histidine-tagged) were subtracted from the nucleocapsid by nickel affinity chromatography. The nucleocapsid was further purified by cation exchange chromatography, dialyzed against 10 mM ammonium bicarbonate, aliquoted and lyophilized. NR-699 has a molecular weight of approximately 46,000 daltons. Using Western blot analysis, NR-699 reacted with rabbit polyclonal sera prepared against the SUMO nucleocapsid fusion, but did not react with rabbit polyclonal sera prepared against a SUMO-3CL protease fusion.
Each vial contains approximately 1.0 mg of NR-699 lyophilized in 10 mM ammonium bicarbonate.